Dual GIP/GLP-1 agonists may be better for patients who havent achieved sufficient weight loss with GLP-1 medications alone, those requiring more aggressive metabolic intervention, individuals who can tolerate the slightly higher side effect rates at maximum doses, and patients seeking the most effective currently available FDA-approved option
However, their release mechanism is more closely tied to ambient glucose levels, making their action more calibrated to actual need
Not full RCT publications
When B12 levels are low, the body may not produce enough healthy red blood cells to carry oxygen throughout the body
When cortisol levels remain persistently elevateda condition known as hypercortisolismsignificant health consequences can develop
The companys website claims that this route of administration has better bioavailability and a quicker onset of action than traditional oral pills. It is unclear what scientific evidence these claims are based on